 |
EDUCATIONAL OVERVIEW As a key patient advocate in acute care settings, hospital based clinicians play a major role in ensuring that appropriate measures are in place for their patients with or at high risk for serious bacterial infections. They cannot only ensure that appropriate preventive and diagnostic measures are performed, but can be an invaluable member of the interprofessional healthcare team involved in clinical decision-making. As the CDC has included specific multidrug-resistant Gram-negative bacteria and C. difficile on their list of serious healthcare threats in the US, hospital clinicians must be aware of the latest approaches to minimize the burden of these infections. This program reviews the latest evidence demonstrating how treatment selection should be guided by patient and pathogen risk factors for poor clinical outcomes. The program also highlights the role of the latest treatment approaches, including the use of newly-approved beta-lactam/beta-lactamase inhibitor combinations for serious Gram-negative infections, and novel approaches for C. difficile infection. TARGET AUDIENCE Optimal management of serious bacterial infections requires contributions from all healthcare professionals involved in the management of patients at risk for these infections. Therefore, this program targets hospital based clinicians who play a role in managing and preventing infections at healthcare institutions. LEARNING OBJECTIVES Upon completing this activity, participants will be able to:
|
EDUCATIONAL FORMAT These Online Presentations are based on the CME Satellite Symposium held in conjunction with Hospital Medicine 2016, SHM’s Annual Meeting
FACULTY
|
|||||||||||||||||||
Accreditation Center for Independent Healthcare Education designates this Enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For questions regarding accreditation, please contact info@jointsponsor.com
Pharmacists
Method of Participation and Instruction for Credit
Disclosure of Conflicts of Interest In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activityRelevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.
|
Disclosures Stuart Johnson, MD has relevant financial relationships with the following commercial interests: Advisory Board: BioK+, Summit Therapeutics, Seres Therapeutics Dr. Johnson discusses the off-label use of following: Metronidazole, rifaximin, nitazoxanide are not FDA-approved for treating CDI, but are commonly used. Advisory Board: Accelerate Diagnostics, Allergan, Astellas Pharma, The Medicines Company, and Merck & Co. Dr. Lewis discusses the off-label use of following: Off-label use of agents for multi-drug resistant Gram-negative organisms in non-FDA-approved sites/infections. Advisory Board: The Medicines Company, Melinta, Shionogi, Tetraphase, Theravance Biopharma, Zavante Therapeutics Dr. Rodvold discusses the off-label use of following: Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Meropenem-RPX7009, Imipenem-Relbactam, Aztreonam-Avibactam, S649266, Plazomicin, POL7080, and BAY 41-6551. Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Hardware/Software Requirements Software/Hardware Connection Speed System Check Copyright Statement Privacy Policy Joint Providership Commercial Support
|
Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 2 contact hours (0.2 CEUs) of continuing pharmacy education credits for participating in this activity. START ACTIVITY |
   |
  |